Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Lazertinib Dose Modification on Effectiveness and Safety in EGFR T790M-Positive Advanced Lung Cancer

NCT05716672 is registered in ClinicalTrials.gov with Pusan National University Hospital as lead sponsor.

NCT NCT05716672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05716672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Lazertinib Dose Modification on Effectiveness and Safety in EGFR T790M-Positive Advanced Lung Cancer
Lead sponsor
Pusan National University Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2023
Completion date
December 31, 2025
Enrollment
200 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer